Although the precise mechanism of this synergism remains to be determined, our data support that WIP1 and JMJD3 are important targets in neuroblastoma and merit further investigation aiming at clinical implementation, especially in combination with each other. The gene discussed is PPM1D; the disease is neuroblastoma.